Évolution fatale du syndrome de Netherthon due à une utilisation excessive de dermocorticoïdes chez un adulte

C, Valette; Ofaiche, J.; Severino, Manuel José Soler; Mazereeuw‐Hautier, J.

doi:10.1016/j.annder.2019.09.003

Cited by 4 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because Netherton syndrome patients have a severe skin barrier defect, excessive percutaneous absorption of topical corticosteroids can impair renal reabsorption and result in aminoaciduria [86]. Prolonged and/or excessive use of topical corticosteroids by NS patients has also been associated with the development of Cushing syndrome, severe skin atrophy, acute adrenal insufficiency or even fatality [87,88]. Excessive use of topical steroids can also aggravate the defective skin barrier by inducing additional loss of stratum corneum.…”

Section: Topical Corticosteroidsmentioning

confidence: 99%

Advances in understanding of Netherton syndrome and therapeutic implications

Petrova

Hovnanian

2020

Expert Opinion on Orphan Drugs

View full text Add to dashboard Cite

Introduction: Netherton syndrome (NS) is a rare and severe ichthyosis characterized by superficial scaling, skin inflammation, a specific hair shaft defect, severe atopic manifestations and multisystemic complications. It is an orphan disease with currently no satisfactory treatment. NS is caused by loss-offunction mutations in SPINK5 encoding the serine protease inhibitor LEKTI. NS patients present with ichthyosiform erythroderma or ichthyosis linearis circumflexa and show considerable clinical variability. Areas covered: Uncontrolled serine protease activity leads to a profound skin barrier defect and the release of pro-inflammatory and pro-allergic mediators by keratinocytes and immune cells. Improved understanding of NS pathogenesis has led to the successful use of repurposed biologics such as intravenous immunoglobulins and anti-IL-17A blockers. Between April 1, 2020 and November 18, 2020, authors searched for NS-relevant information in the following databases: MEDLINE, DrugBank, ClinicalTrials.gov, and patent datasets accessed through lens.org. Expert opinion: Specific KLK5 and/or KLK7 inhibitors represent the most promising disease-modifying treatments. They are currently being developed by several companies. Comprehension of the determinants of NS variability, flares and modification over time will be the foundation for precision medicine. While improved knowledge of the inflammatory and allergic pathways involved is still needed, clinical trials using repurposed biologics have already begun.

show abstract

Section: Topical Corticosteroidsmentioning

confidence: 99%